LAG3 and melanoma: More recently, relatlimab, a lymphocyte-activation gene 3 (LAG-3)–blocking antibody that functions to reduce LAG-3 mediated T cell inhibition, has been developed and used as an additional immunotherapy for melanoma [17,18].